Last reviewed · How we verify
PF-06821497 Treatment C (pf-06821497-treatment-c)
At a glance
| Generic name | pf-06821497-treatment-c |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Vessel puncture site bruise
- Nail avulsion
- Neck pain
- Disturbance in attention
- Eyelid pain
- abdominal discomfort
- Abdominal pain
- Constipation
- Nausea
- Vessel puncture site pain
- Fall
Key clinical trials
- A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (PHASE1)
- A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06821497 Treatment C CI brief — competitive landscape report
- PF-06821497 Treatment C updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI